Avantor's revenue has hovered near $1.6B to $1.7B across the reported quarters with no durable acceleration, while gross margin has held in a narrow 31.5% to 34.1% band and operating margin in recent quarters sits around 7% to 8%, well below peers such as Thermo Fisher at 18.2%.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue has been flat at roughly $1.6B to $1.7B with year-over-year growth ranging from about -6% to +5%, and gross margin of 31.5% to 34.1% is steady but operating margin of roughly 7% to 8% in recent quarters leaves limited headroom against pricing or volume pressure.
The stock is considered deeply oversold with minimal downside to estimates, presenting a contrarian investment opportunity due to its undervaluation and improving fundamentals.
Avantor operates as a leading life science tools company, providing mission-critical products and services to the life sciences and advanced technology sectors.
There is material upside potential from a potential takeout, given the stock's significant drop despite only modest reductions in revenue and EPS estimates.
Trailing total returns as of 11/7/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 28, 2026 | $0.22+5.3% vs $0.21 | $1.7B+3.4% vs $1.6B |
Q3 2026 Jul 29, 2026 | $0.21+9.7% vs $0.19 | $1.7B+5.1% vs $1.6B |
Q2 2026 Apr 29, 2026 | $0.17+8.3% vs $0.16 | $1.6B+2.5% vs $1.5B |
Q1 2026 Feb 11, 2026 | $0.22+4.8% vs $0.21 | $1.7B+1.6% vs $1.6B |
RADNOR, Pa., Oct. 26, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, welcomes Mikey Santiago as its new Chief Information Officer.
The market is regaining confidence in Avantor's ability to grow organically and in Emmanuel Ligner's turnaround plan. Biopharma company Regeneron reported a solid set of results, with key drug Dupixent continuing to outpace our and the market's growth expectations. Building products company Fortune Brands Innovations saw its stock price decline in Q3, retracing Q2's positive move related to excitement over Jesse Singh's appointment as CEO.
AVTR's improving commercial execution, specialty product strength and raised 2026 outlook signal recovery potential despite lingering demand challenges.
Shares of Avantor, Inc. (NYSE: AVTR - Get Free Report) have earned a consensus recommendation of "Hold" from the eighteen ratings firms that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and two have issued a buy rating on the
Benchmark AVTR against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Avantor, Inc. (AVTR)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $15.47 | $10.46B | 31.24 | -3.41% | 5.08% | 5.96% | — | |
| $694.76 | $258.19B | 36.39 | 3.91% | 14.96% | 13.3% | 0.24% | |
| $230.25 | $161.86B | 37.58 | 2.9% | 16.91% | 8.18% | 0.54% | |
| $128.25 | $717.67M | 153.81 | 3.38% | 1.92% | 2.59% | 0.49% | |
| $112.71 | $4.99B | 29.47 | 3.62% | 3.49% | 9.98% | — | |
| $457.60 | $34.22B | 459.62 | 6.99% | 1.75% | 0.81% | — |
Avantor, Inc. (AVTR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Avantor, Inc. (AVTR) SEC filings — annual & quarterly reports (10-K, 10-Q)
Oct 28, 2026·SEC
Jul 29, 2026·SEC
Jul 17, 2026·SEC
Get notified when AVTR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Avantor, Inc. (AVTR) stock FAQ — growth, dividends, profitability & financials explained
Avantor, Inc. (AVTR) reported $6.64B in revenue over the trailing twelve months. Revenue was $6.55B in fiscal year 2025. That is 848% more than the $691.3M of fiscal year 2016.
Avantor, Inc. (AVTR) grew revenue by 0.9% over the trailing twelve months, compared with the twelve months before.
Yes. Avantor, Inc. (AVTR) earned $337.2M in net income over the trailing twelve months (a 5.1% net margin).
Avantor, Inc. (AVTR) had a return on equity (ROE) of 6.0% over the trailing twelve months. That is below the market's typical 10-15%.
Avantor, Inc. (AVTR) generated $439.2M in free cash flow over the trailing twelve months.
